{"id":"isv-303","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1077","moleculeType":"Small molecule","molecularWeight":"334.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for ISV-303 remain proprietary, Sun Pharmaceutical's development of this Phase 3 candidate suggests it targets immune checkpoint regulation to overcome tumor-mediated immune suppression. The drug is intended to restore T-cell function and promote anti-tumor immunity in cancer patients.","oneSentence":"ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:21.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under clinical evaluation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT07090044","phase":"PHASE4","title":"Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period","status":"COMPLETED","sponsor":"Retina Research Institute, LLC","startDate":"2021-08-20","conditions":"Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema","enrollment":77},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT06130384","phase":"PHASE4","title":"Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2021-03-01","conditions":"Pain, Intravitreal Injection, Pain, Acute","enrollment":97},{"nctId":"NCT05107921","phase":"PHASE2","title":"Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2021-11-01","conditions":"Familial Exudative Vitreoretinopathies","enrollment":39},{"nctId":"NCT04343222","phase":"PHASE4","title":"Control of Pain in Intravitreal Injections Using Topical NSAIDs","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-27","conditions":"Intravitreal Injections, IVI","enrollment":46},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01808547","phase":"PHASE3","title":"Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-05","conditions":"Ocular Inflammation","enrollment":268},{"nctId":"NCT01190878","phase":"PHASE1, PHASE2","title":"Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2010-08","conditions":"Ocular Inflammation","enrollment":169},{"nctId":"NCT01478555","phase":"PHASE2","title":"A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-01","conditions":"Dry Eye Disease","enrollment":""},{"nctId":"NCT01387464","phase":"PHASE2","title":"Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2011-07","conditions":"Cataract","enrollment":60},{"nctId":"NCT01576952","phase":"PHASE3","title":"Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2012-07","conditions":"Ocular Inflammation","enrollment":268},{"nctId":"NCT05006898","phase":"PHASE1","title":"Compound to Control Presbyopia Symptoms","status":"COMPLETED","sponsor":"Optall Vision","startDate":"2020-06-01","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT05001243","phase":"PHASE1","title":"Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-10","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT05006911","phase":"PHASE1","title":"Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms","status":"UNKNOWN","sponsor":"Optall Vision","startDate":"2021-08-14","conditions":"Presbyopia","enrollment":11},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT03751059","phase":"PHASE4","title":"NSAID vs Steroid in Trabeculectomy Wound Management","status":"UNKNOWN","sponsor":"Cindy Hutnik","startDate":"2020-11","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT00758784","phase":"PHASE2","title":"Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-08-13","conditions":"Dry Eye Disease","enrollment":38},{"nctId":"NCT01212471","phase":"PHASE3","title":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":840},{"nctId":"NCT03521791","phase":"PHASE4","title":"Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-12-13","conditions":"Pterygium, Ocular Pain, Ocular Inflammation","enrollment":166},{"nctId":"NCT01535443","phase":"PHASE1","title":"Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2011-09","conditions":"Inflammation, Cataract","enrollment":35},{"nctId":"NCT04022811","phase":"PHASE4","title":"Effect of Bromfenac on Pain Related to Pterygium Surgery","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-10","conditions":"Pterygium, Pain","enrollment":60},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":"Treatment of Ocular Inflammation Associated With Cataract Surgery","enrollment":57},{"nctId":"NCT03831984","phase":"PHASE4","title":"Topical Bromfenac for Intraoperative Miosis and Pain Reduction","status":"UNKNOWN","sponsor":"Hospital de La Luz","startDate":"2018-03-01","conditions":"Cataract","enrollment":60},{"nctId":"NCT02973880","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2017-10-15","conditions":"Cataract Extraction, Cataract","enrollment":180},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":"Cataract, Retinal Edema, Inflammation","enrollment":50},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT01189864","phase":"","title":"Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2010-02-01","conditions":"Keratoconus, Ectasia, Degeneration","enrollment":3493},{"nctId":"NCT01024322","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-10-01","conditions":"Keratoconus, Ectasia, Degeneration","enrollment":1189},{"nctId":"NCT01097447","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-12-01","conditions":"Keratoconus, Ectasia, Degeneration","enrollment":2619},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT03106402","phase":"","title":"Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2013-10-01","conditions":"Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification","enrollment":316},{"nctId":"NCT00438243","phase":"PHASE2","title":"Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-05","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT02681679","phase":"NA","title":"Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":"Cataract","enrollment":60},{"nctId":"NCT00703781","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":126},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT01367249","phase":"PHASE3","title":"Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Pain, Inflammation, Cataract","enrollment":440},{"nctId":"NCT00423007","phase":"PHASE3","title":"Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Allergic Conjunctivitis","enrollment":90},{"nctId":"NCT00198445","phase":"PHASE3","title":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2003-05","conditions":"Postoperative Complications, Cataract","enrollment":527},{"nctId":"NCT00585975","phase":"PHASE2","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-10","conditions":"Cataract Surgery","enrollment":568},{"nctId":"NCT00333918","phase":"PHASE3","title":"Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Pain, Inflammation","enrollment":522},{"nctId":"NCT00853970","phase":"PHASE3","title":"Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Pain, Inflammation","enrollment":299},{"nctId":"NCT00704418","phase":"PHASE3","title":"Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Cataract","enrollment":156},{"nctId":"NCT01193504","phase":"PHASE4","title":"Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification","status":"UNKNOWN","sponsor":"Innovative Medical","startDate":"2010-09","conditions":"Pseudophakia, Cataract Surgery","enrollment":100},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":"Cataracts","enrollment":49},{"nctId":"NCT01001806","phase":"PHASE4","title":"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":"Cataracts","enrollment":126},{"nctId":"NCT01021761","phase":"PHASE4","title":"A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":"Cataracts","enrollment":126},{"nctId":"NCT01023724","phase":"PHASE4","title":"A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)","status":"COMPLETED","sponsor":"Bucci Laser Vision Institute","startDate":"2009-12","conditions":"Post Operative Anterior Chamber Inflammation (Flare)","enrollment":50},{"nctId":"NCT00805233","phase":"PHASE2","title":"Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-12","conditions":"Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT00758628","phase":"PHASE4","title":"Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-08","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200},{"nctId":"NCT00595543","phase":"PHASE4","title":"Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-01","conditions":"Acute Pseudophakic Cystoid Macular Edema","enrollment":166},{"nctId":"NCT00520260","phase":"PHASE4","title":"Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase","status":"COMPLETED","sponsor":"Florida Eye Microsurgical Institute","startDate":"2007-08","conditions":"Dry Eye Disease, Ocular Comfort","enrollment":42},{"nctId":"NCT00377546","phase":"PHASE4","title":"Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Vitrectomy","enrollment":""},{"nctId":"NCT00469781","phase":"PHASE4","title":"Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening","status":"COMPLETED","sponsor":"Center For Excellence In Eye Care","startDate":"2007-05","conditions":"Cystoid Macular Edema,, Retinal Thickening","enrollment":95},{"nctId":"NCT00469690","phase":"PHASE4","title":"Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2007-05","conditions":"Cataract","enrollment":58},{"nctId":"NCT00347503","phase":"PHASE4","title":"Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Cataract","enrollment":""},{"nctId":"NCT00491166","phase":"PHASE1","title":"Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2007-06","conditions":"Diabetic Macular Edema","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ISV-303","genericName":"ISV-303","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway. Used for Cancer (specific indication under clinical evaluation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}